Back to News
1

Feature Story

Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum

Mar 25, 2025 · financialpost.com
Rakovina Therapeutics Inc., a biopharmaceutical company based in Vancouver, announced that two of its abstracts have been accepted for presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The company is utilizing artificial intelligence (AI) to develop innovative cancer therapies, focusing on AI-powered drug discovery. One of the abstracts details the discovery of novel PARP1-selective inhibitors for brain tumors, addressing challenges like poor blood-brain barrier permeability and off-target effects. The second abstract highlights the development of a CNS-penetrating ATR inhibitor, aimed at improving treatment for brain tumors by overcoming current limitations in blood-brain barrier permeability.

Rakovina's AI-driven approach, using platforms like Deep Docking™ and Enki™, allows for rapid identification and optimization of potential drug candidates, significantly accelerating the drug discovery process. The company's work is supported by access to advanced lab infrastructure at the University of British Columbia. Rakovina aims to advance its preclinical pipeline, targeting DNA-repair vulnerabilities in hard-to-treat cancers such as breast, ovarian, prostate, and brain cancers. The company is poised to make significant contributions to oncology, with plans to collaborate with pharmaceutical partners for clinical trials.

Key takeaways

  • Rakovina Therapeutics is presenting two AI-powered cancer therapy abstracts at the 2025 AACR Annual Meeting.
  • The company uses AI to develop novel PARP1-selective inhibitors and CNS-penetrating ATR inhibitors for brain tumors.
  • Rakovina's AI platforms, Deep Docking™ and Enki™, significantly accelerate drug discovery and candidate evaluation.
  • The company's innovations target DNA-repair vulnerabilities in hard-to-treat cancers, with a focus on advancing therapies to clinical trials.
View Full Article

Discussion (0)

Be the first to comment!